05:39 PM EDT, 09/24/2025 (MT Newswires) -- Immuneering ( IMRX ) reported updated results late Wednesday from a Phase 2a trial of atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing 86% overall survival at nine months versus about 47% for the standard of care.

Progression-free survival was 53% at nine months compared with roughly 29% for the standard of care. The company expects regulatory feedback on pivotal trial plans in Q4 and anticipates beginning a Phase 3 study by year-end.

Separately, Immuneering ( IMRX ) has launched a concurrent $25 million private placement to Sanofi. Proceeds are intended to fund clinical development and for general corporate purposes.

Immuneering ( IMRX ) stock closed up 7.5% Wednesday and climbed another 38% after hours. Volume was 872,000 shares, near the daily average of 918,000.